Ann: onCARlytics with ARTEMIS T cells show anti-tumour activity, page-66

@JimmyBgood the combination immunotherapy, onCARlytics, unleashes a CD19-expressing oncolytic virus CF33-CD19 to target and eradicate solid tumours that are otherwise difficult to treat with CAR T therapy alone. The figures in the poster presentation discuss onCARlytics which is defined therein on the RHS as CF33 in combination with CD19t. The combination of the CD-19-directed CAR T with the CD19-encoding OV (i.e., CF33) is what enables the tumour to not only be targeted (i.e., through CD19 expression), but destroyed, by the oncolytic virus (OV) CF33. CD19 is not normally expressed on solid tumours, and as we know CAR T's on their own have only been successful in treating blood cancers, as opposed to solid tumours. What gives the onCARlytics platform the punch or knockout blow as it were is the addition of CF33, (i.e, infused with CD19). Without the OV there would be no tumour eradication IMO.

Opinions only